Roche Collaborates with Icagen for the Development of Drug Candidates for Neurological Disorders

 Roche Collaborates with Icagen for the Development of Drug Candidates for Neurological Disorders

Roche Collaborates with Icagen for the Development of Drug Candidates for Neurological Disorders

Shots:

  • Icagen to receive upfront, up to $274M milestones and royalties on sales from Roche and is responsible for all preclinical activities
  • Roche to fund the program and will perform further development and commercialization activities
  • The focus of the collaboration is to develop pre-clinical stage ion channel modulators using Icagen’s drug discovery platform, for targeting ion channel in neurons

Click here to read full press release/ article | Ref: Icagen | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post